New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SNY;NVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
13:55 EDTSNYRBC thinks Intercept values itself more than any bidder can pay
RBC Capital analyst Michael Yee believes Intercept Pharmaceuticals (ICPT) thinks it is worth more than a bidder would be willing to pay at this time. Suitor interest is not surprising given Intercept's pending approval in the summer, but a near-term takeover is unlikely since the FDA hasn't even held a panel meeting for the company's lead drug OCA, Yee tell investors in a research note after Reuters reported that the company received interest and is exploring a possible sale. The analyst thinks Intercept could be synergistic for companies like Gilead (GILD), Merck (MRK), Bristol-Myers (BMY), Sanofi (SNY) and AstraZeneca (AZN). Yee has an Outperform rating on stock with a $300 price target. Intercept is rallying 25%, or $24.07, to $118.36 in afternoon trading.
February 11, 2016
07:17 EDTSNYLeerink to hold a conference
Subscribe for More Information
February 10, 2016
09:32 EDTNVONovo Nordisk moves higher in early trading
Subscribe for More Information
February 9, 2016
12:25 EDTSNYRegeneron price target lowered to $443 from $607 at Piper Jaffray
Subscribe for More Information
08:08 EDTSNYSanofi sees FY16 business EPS to be broadly stable at CER
Subscribe for More Information
05:28 EDTSNYSanofi reports Q4 business EPS down 5.8% to EUR 1.31
Subscribe for More Information
February 8, 2016
10:00 EDTNVOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: A-Mark Precious Metals (AMRK) downgraded to Neutral from Buy at B. Riley... Antero Midstream (AM) downgraded to Neutral from Outperform at Baird... AstraZeneca (AZN) downgraded to Hold from Buy at HSBC... Baker Hughes (BHI) downgraded to Equal Weight at Morgan Stanley... Brixmor (BRX) downgraded to Neutral from Outperform at Boenning & Scattergood... CBOE Holdings (CBOE) downgraded to Underperform from Outperform at CLSA... Cisco (CSCO) downgraded to Buy from Conviction Buy at Goldman... Citi Trends (CTRN) downgraded to Neutral from Buy at MKM Partners... Commerzbank (CRZBY) downgraded to Underperform from Market Perform at Keefe Bruyette... DexCom (DXCM) downgraded to Neutral from Outperform at Baird... EnLink Midstream (ENLC) downgraded to Underperform from Outperform at Baird... Energy Transfer Equity (ETE) downgraded to Neutral from Outperform at Baird... Energy Transfer Partners (ETP) downgraded to Neutral from Outperform at Baird... Eversource (ES) downgraded to Equal Weight from Overweight at Barclays... Genesis Healthcare (GEN) downgraded to Sell from Neutral at UBS... Givaudan (GVDNY) downgraded to Neutral from Buy at Goldman... HSBC (HSBC) downgraded to Underweight from Equal Weight at Morgan Stanley... Nomura (NMR) downgraded to Hold from Buy at Deutsche Bank... Novo Nordisk (NVO) downgraded to Sell from Neutral at UBS... ONEOK Partners (OKS) downgraded to Underperform from Neutral at Baird... ONEOK (OKE) downgraded to Neutral from Outperform at Baird... PPL Corp. (PPL) downgraded to Hold from Buy at Evercore ISI... Plains All American (PAA) downgraded to Underperform from Outperform at Baird... Plains GP Holdings (PAGP) downgraded to Underperform from Neutral at Baird... Quanta Services (PWR) downgraded to Neutral from Buy at UBS... Ralph Lauren (RL) downgraded to Neutral from Overweight at Atlantic Equities... Sparton (SPA) downgraded to Market Perform from Outperform at Barrington... Tableau (DATA) downgraded to Equal Weight at Morgan Stanley... Tallgrass Energy GP (TEGP) downgraded to Neutral from Outperform at Baird... WisdomTree (WETF) downgraded to Underperform from Market Perform at Keefe Bruyette.
06:28 EDTSNYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
05:36 EDTNVONovo Nordisk downgraded to Sell from Neutral at UBS
Subscribe for More Information
February 4, 2016
11:13 EDTNVONovo Nordisk management to meet with Jefferies
Meeting to be held in Geneva on February 11 hosted by Jefferies.
February 2, 2016
11:09 EDTSNYSanofi plans to cut 600 jobs in France over three years, Bloomberg reports
Subscribe for More Information
08:36 EDTNVOPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:24 EDTSNYSanofi, Merck mulling exiting vaccine JV, Bloomberg reports
Subscribe for More Information
05:19 EDTSNYSanofi Pasteur launches R&D project targeting prevention of Zika virus infection
Subscribe for More Information
January 29, 2016
13:38 EDTSNYAmgen wins right to allege willful infringement in Praluent suit, Markman says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use